← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE › Progestogens and estrogens, fixed combinations
medroxyprogesterone and ethinylestradiol
G03AA08
Forms & Strengths
- Tablet: medroxyprogesterone 10mg and ethinylestradiol 0.02mg
- Tablet: medroxyprogesterone 2.5mg and ethinylestradiol 0.035mg
- Injection: medroxyprogesterone 150mg/ml and ethinylestradiol 10mcg/ml
Adult Dosing
- 1 tablet PO daily for 21 days, then 7 days off
- 1 injection IM every 12 weeks
- Adjust dose based on individual response and medical history
Pediatric Dosing
- Not recommended under 16 years of age
- Use with caution in adolescents with known or suspected estrogen-dependent malignancies
Indications
- Contraception
- Treatment of moderate to severe dysmenorrhea
- Treatment of endometriosis
- Abnormal uterine bleeding
Mechanism of Action
- Medroxyprogesterone: progestin receptor agonist
- Ethinylestradiol: estrogen receptor agonist
- Inhibits ovulation and thickens cervical mucus
Contraindications
- Known or suspected pregnancy
- Severe liver disease
- Thrombophlebitis or thromboembolic disorders
- Undiagnosed vaginal bleeding
- Breast cancer or other estrogen-dependent cancer
Adverse Reactions
- Nausea and vomiting
- Breast tenderness
- Headache
- Weight gain
- Mood changes
Drug Interactions
- Inducers of hepatic cytochrome P450 enzymes (e.g. rifampin)
- Inhibitors of hepatic cytochrome P450 enzymes (e.g. ketoconazole)
- Anticonvulsants (e.g. phenytoin)
- Antibiotics (e.g. rifampin)
Curated Content: Needs Vetting Before Put to Clinical Use